If You Invested in Hangzhou Tigerme (HNGZY)

HANGZHOU TIGRMD UNSP/ADR (HNGZY) represents an interest in Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed”), which is described in company communications as a global Contract Research Organization (CRO) and a leading global provider of integrated research and development solutions for the biopharmaceutical and medical device industry. Under its A-share and H-share listings (stock code 300347.SZ / 3347.HK), Tigermed highlights a service platform that spans from preclinical development through clinical trials to commercialization for pharmaceutical and medical device products.

Tigermed states that it collaborates with thousands of customers worldwide and operates through an extensive international network. Company disclosures describe more than 100 subsidiaries and around 180–180+ service locations, with employees distributed across Asia Pacific, Europe, North America, Latin America, and Africa. Through this network, Tigermed supports clinical research projects, regulatory activities, and related services for drug and device development in multiple regions.

Business focus and service areas

According to its public news releases, Tigermed focuses on clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products. The company divides its activities into areas such as clinical trial solutions and clinical-related and laboratory services. Within these areas, Tigermed communications refer to work on drug clinical trials, medical device and in vitro diagnostic (IVD) projects, regulatory affairs, pharmacovigilance, data management and statistical analysis, site management services, independent central imaging, and laboratory services through its subsidiary Frontage Holdings.

Company updates indicate that Tigermed has participated in a large number of ongoing drug clinical trials and medical device & IVD projects in China and overseas. Its regulatory affairs operations report accumulated experience in hundreds of projects, including U.S. FDA investigational new drug (IND) projects and China-focused regulatory work. Tigermed also reports experience supporting approvals of Class I innovative drugs and innovative medical devices in China over multiple years.

Global footprint and international expansion

Tigermed positions itself as a global CRO with a broad geographic footprint. Company news describes operations or employees in dozens of countries across Asia Pacific, Europe, North America, Latin America and Africa, and notes that Tigermed has conducted multi-regional clinical trials (MRCTs) in numerous countries and regions. The firm reports that it has handled MRCT projects across North America, Asia Pacific, Latin America, Europe, and Africa, and that it has ongoing and cumulative experience with multi-regional and single-region overseas clinical trials.

To deepen its presence in key markets, Tigermed has used acquisitions and new offices. Public announcements describe acquisitions of Marti Farm, a European CRO focused on pharmacovigilance, clinical operations, regulatory affairs and medical affairs, and the acquisition of Micron, a Japan-based imaging CRO specializing in medical imaging and clinical trial services. Tigermed also reports acquiring Medical Edge in Japan and expanding lab capabilities in Europe through Frontage Holdings’ acquisition of preclinical DMPK and bioanalytical business assets in Italy. In addition, the company has highlighted new offices and facilities in locations such as the United Kingdom, Netherlands, Argentina, and multiple cities in China.

Technology, digital platforms and decentralized trials

Company disclosures emphasize the use of technology and digital tools in clinical research. Tigermed reports launching and deploying platforms for Decentralized Clinical Trials (DCT), including remote monitoring systems, subject eligibility discussion systems, electronic source data repository (ESDR) deployments, and eSource-to-EDC (E2E) models. It states that a portion of its ongoing clinical trials have adopted hybrid DCT models.

Tigermed also reports internal development of technology platforms such as a Risk Based Quality Management (RBQM) system, an e-Clinical trial Patient Management (eCPM) system, and AI-enabled tools. Disclosures mention the launch of the YiYa AI Intelligent Translation Platform and an AI LLM platform referred to as YiYa AI LLM, which are described as supporting translation and AI-enabled business growth in areas related to clinical development and medical translation.

Laboratory and imaging services

Through its subsidiary Frontage Holdings, Tigermed describes a range of laboratory services that support clinical and preclinical research. Company communications reference bioequivalence services, pharmacodynamics and analysis work, DMPK and bioanalytical laboratories, and safety assessment centers that have obtained regulatory certifications such as GLP accreditation from relevant authorities. Frontage’s expansion in regions including China and Europe is highlighted as part of Tigermed’s broader lab services segment.

In imaging, Tigermed reports independent central imaging services that support clinical trials and product approvals. The acquisition of Micron, an imaging CRO headquartered in Tokyo, is presented as a way to strengthen medical imaging capabilities and clinical trial imaging support, particularly in Japan and the Asia-Pacific region. Micron’s expertise in imaging biomarkers, AI-powered imaging support, and centralized imaging review is described as being integrated into Tigermed’s network under Tigermed Japan.

Site management, data and support functions

Tigermed communications describe a Site Management Organization (SMO) business with thousands of ongoing projects and contributions to approvals of Class I innovative drugs in China. The company’s Clinical Trial Sites of Excellence (“E-Site”) program is presented as a network of collaborative sites, strategic cooperation centers, and key cooperation centers across China and other regions, intended to support clinical trial execution.

Data Management & Statistical Analysis (DMSA) is another area emphasized in Tigermed’s disclosures. The company reports hundreds of ongoing DMSA projects and hundreds of global clients, and notes that this function has assisted in commercialization and approvals of innovative drugs in China and overseas markets. Tigermed also highlights growth in medical translation services and pharmacovigilance projects, including local teams in Europe and the United States.

Corporate development and headquarters

Tigermed is based in Hangzhou, China, and has reported the commencement of construction on a global headquarters. It has also announced the opening of an International Headquarters in Hong Kong, which is described as a hub for overseas functional support, business development, and coordination of global projects. The company notes that it established a Hong Kong office in 2011 and later listed on the Hong Kong Stock Exchange, forming an “A + H” dual-capital platform alongside its Shenzhen listing.

In addition to physical expansion, Tigermed communications describe long-term strategies focused on globalization, digitalization, and innovation-driven growth. The company reports initiatives such as special business units for specific therapeutic areas, a Clinical Operations Strategy Committee, and a Solutions Business Unit aimed at long-term cooperation with multinational companies.

Industry role and recognition

Across multiple years of disclosures, Tigermed presents itself as a major participant in China’s clinical service and CRO markets, citing market share figures in China’s clinical outsourcing market and its role in supporting Class I innovative drug approvals. It also reports participation in vaccine clinical services, including COVID-19 vaccine projects and overseas vaccine MRCTs, and notes involvement in real-world studies across therapeutic areas such as oncology, rare diseases, orthopaedics and others.

The company reports recognition from rating agencies and industry organizations, including ESG ratings from MSCI and the Shenzhen Stock Exchange’s CNI ESG Ratings, as well as awards related to medical device service provision, employer branding, digital platform practices, and language service rankings for its medical translation business.

Position within the professional, scientific and technical services sector

Within the broader Professional, Scientific, and Technical Services sector and the testing and laboratory-related space, Tigermed’s disclosures emphasize its role as a contract research partner to biopharmaceutical and medical device companies. Its activities span clinical trial operations, regulatory and safety services, data and statistical analysis, site management, imaging, and laboratory testing through affiliated entities. For investors reviewing HNGZY, these disclosures provide context on how the underlying company positions itself in the global CRO and clinical research ecosystem.